There is provided a compound which is a histone deacetylase (HDAC) inhibitor, or a pharmaceutically acceptable ester, amide, solvate or salt thereof, for use in: (I) treating or preventing a pathological condition associated with excess fibrin deposition and/or thrombus formation

The present invention relates to compounds which are phospholipid derivatives of valproic acid to compositions comprising said compounds and their use for treating epilepsy migraine bipolar disorders and pain.

There is provided a compound which is a histone deacetylase (HDAC) inhibitor, or a pharmaceutically acceptable ester, amide, solvate or salt thereof, for use in: (I) treating or preventing a pathological condition associated with excess fibrin deposition and/or thrombus formation

The subject of the invention is pharmaceutical microspheres containing as active principle a mixture of valproic acid and of one of its pharmaceutically acceptable salts in combination with a matrix vehicle selected from glycerol esters hydrogenated oils esterified polyethylene glycols waxes and their mixtures.

Biocompatible, bioerodible, sustained release drug delivery system formulated as implants, microspheres and high viscosity hyaluronic acid solutions comprise valproic acid as therapeutic agent and a biodegradable polymer, the system being effective, when placed intraocular (such as into the subtenon space or into the vitreous) to treat a retinal disease or condition.

Biocompatible bioerodible sustained release drug delivery system formulated as implants microspheres and high viscosity hyaluronic acid solutions comprise valproic acid as therapeutic agent and a biodegradable polymer the system being effective when placed intraocular (such as into the subtenon space or into the vitreous) to treat a retinal disease or condition.